作者：
Emily,Golden [1]
;
David,Allen [2]
;
Alexander,Amberg [3]
;
Lennart T,Anger [4]
;
Elizabeth,Baker [5]
;
Szczepan W,Baran [6]
;
Frank,Bringezu [7]
;
Matthew,Clark [8]
;
Guillemette,Duchateau-Nguyen [9]
;
Sylvia E,Escher [10]
;
Varun,Giri [11]
;
Armelle,Grevot [12]
;
Thomas,Hartung [13]
;
Dingzhou,Li [14]
;
Laura,Lotfi [15]
;
Wolfgang,Muster [9]
;
Kevin,Snyder [16]
;
Ronald,Wange [16]
;
Thomas,Steger-Hartmann [17]
作者单位：
Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
[1]
Inotiv, Inc., Morrisville, NC, USA.
[2]
Sanofi, Preclinical Safety, Frankfurt, Germany.
[3]
Genentech Inc., South San Francisco, CA, USA.
[4]
Physicians Committee for Responsible Medicine, Washington, DC, USA
[5]
VeriSim Life, San Francisco, CA, USA.
[6]
Merck Healthcare KGaA, Chemical & Preclinical Safety, Darmstadt, Germany.
[7]
Charles River Laboratories, now KALOS Technologies, Philadelphia, PA, USA.
[8]
Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
[9]
Fraunhofer ITEM, Hannover, Germany.
[10]
BASF SE, Experimental Toxicology and Ecology, 67056 Ludwigshafen am Rhein, Germany.
[11]
Novartis Institute for Biomedical Research, Novartis AG, Basel, Switzerland.
[12]
Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.;CAAT-Europe, University of Konstanz, Konstanz, Germany.
[13]
Pfizer, Global Biometrics and Data Management, Groton, CT, USA.
[14]
Charles River Laboratories, Boston, MA, USA
[15]
Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA.
[16]
Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.
[17]
DOI
10.14573/altex.2310041
PMID
38043132
发布时间
2024-07-29
换一批
换一批
